1 2	COVID-19 vaccines uptake: Public knowledge, awareness, perception and acceptance among adult Africans
3	John K. Ahiakpa ^{1&19¶} , Nanma T. Cosmas ^{2¶} , Felix E. Anyiam ^{3¶} , Kingsley O. Enalume ^{4&} , Ibrahim
4	Lawan ^{5&} , Ijuptil B. Gabriel ^{6&} , Chinonyelum L. Oforka ^{7&} , Hamze G. Dahir ^{8¶} , Salisu T. Fausat ^{9^} ,
5	Maureen A. Nwobodo ¹⁰ [^] , Getrude P. Massawe ¹¹ [^] , Adachukwu S. Obagha ¹² [^] , Debra U. Okeh ¹³ [^] ,
6	Benjamin Karikari ^{14&19^} , Samuel T. Aderonke ^{15^} , Olushola M. Awoyemi ^{16^} , Idowu A. Aneyo ^{17^} ,
7	Funmilayo V. Doherty ^{18^}
8 9 10	 ^{#a1}Research Desk Consulting Limited, Kwabenya-Accra, Ghana. ² Department of Medical Microbiology, Faculty of Clinical Sciences, College of Health Sciences,
11	University of Jos, Nigeria.
12 13	 ³ Centre for Health and Development, University of Port Harcourt, River State, Nigeria. ⁴ Department of Electrical and Electronic Engineering, Federal University of Petroleum Descurres, Effurm Data State, Nigeria.
14 15	⁵ School of Biology University of St Andrews St Andrews UK
16	⁶ Modibbo Adama University, Yola Department of Biochemistry School of Life Sciences,
17	Adamawa State, Girei, Nigeria.
18	⁷ Department of Zoology, University of Lagos, Akoka-Yaba, Lagos, Nigeria.
19	⁸ School of Public Health and Nutrition, Amoud University Borama, Awdal, Somaliland,
20	⁹ Department of Zoology and Environmental Biology, Olabisi Onabanjo University, Ago-Iwoye.
21	Ogun State.
22	¹⁰ Public Health Department of Gregory University Uturu, Abia State, Nigeria.
23	¹² African Pagional Postgraduata Programma in Insact Science, University of Chang, Lagon
24 25	Ghana
25	¹³ Department of Community Medicine Federal Medical Centre Umuahia Abia State Nigeria
27	¹⁴ Department of Crop Science, University for Development Studies, Tamale, Ghana,
28	¹⁵ Department of Biochemistry, Faculty of Basic Medical Sciences, University of Lagos.
29	¹⁶ Department of Environmental Toxicology, The Institute Environmental and Human Health,
30	Texas Tech University, Lubbock, USA.
31	¹⁷ Department of Zoology, University of Lagos, Akoka-Yaba, Lagos, Nigeria.
32	¹⁸ Yaba College of Technology, Lagos, Nigeria.
33	^{#019} Organisation of African Academic Doctors, OAAD., Off Kamiti Road, Nairobi, Kenya.
34	[^] Membership of the INASP/AuthorAID Online Journal Club is provided in the
35	Acknowledgments
30 37	Corresponding Author
38	Email: jonahiakpa@outlook.com (JKA)
39	
40	

41 Abstract

Introduction: The willingness of Africa's population to take the COVID-19 vaccines is critical to the efficiency of national immunisation programmes. This study surveys the views of adult African inhabitants toward vaccination and the possibility of participating or not participating in governments' efforts to get citizens vaccinated.

Method: A cross-sectional online survey of adult Africans was undertaken from December 2020 to March 2021. Responses were anonymised. The Pearson Chi-square test was performed to determine whether or not there were any variations in knowledge, awareness, perception and acceptance of the COVID-19 vaccines among the participants. Binomial logistic regression was used to evaluate the factors associated with willingness to accept COVID-19 vaccines and participate in immunisation programmes.

Results: The results indicate that COVID-19 vaccines are more likely to be used by adult Africans over the age of 18 who are largely technologically savvy (55 percent) if the vaccine is made broadly available. A total of 33 percent of those who responded said they were unlikely to receive the vaccine, with another 15 percent stating they were undecided. Aside from that, we found that vaccine hesitancy was closely associated with socio-demographic characteristics such as age, gender, education and source of information. We also found that there were widespread conspiracies and myths about the COVID-19 vaccines.

Conclusion: More than two-thirds of African adults who participated in the survey indicated 59 they would not receive the COVID-19 vaccine, with majority of them expressing skepticisms 60 61 about the vaccine's efficacy. It is possible that many of the people who would not be vaccinated would have an impact on the implementation of a COVID-19 immunisation programme that is 62 meant for all of society. Majority of the respondents were unwilling to pay for the COVID-19 63 64 vaccines when made available. An awareness campaign should be focused on promoting the benefits of vaccination at the individual and population levels, as well as on taking preemptive 65 66 actions to debunk misconceptions about the vaccines before they become further widespread.

67

68 **Key words:** Africa, vaccination, public health; vaccine hesitancy; readiness; conspiracy theories

- 69
- 70
- 71

72 Introduction

73 Infectious diseases have caused untold suffering around the world. Novel pathogenic infections 74 have triggered numerous disease outbreaks and epidemics on the planet in recent decades. 75 SARS-CoV-2, a new strain of coronavirus from Wuhan, China, sparked the world's vilest 76 pandemic ever [1]. Due to its global reach, it was first labeled an epidemic before being upgraded to a pandemic and finally an infodemic [2]. On February 11, 2020, the World Health 77 Organisation (WHO) named it coronavirus disease 2019 (COVID-19) [3]. With 96 % genomic 78 79 identity to the horseshoe bat virus RaTG13, Rhinolophus affinis, SARS-CoV-2 is an enclosed, single-stranded positive-sense RNA virus. A 5'UTR, followed by ORF1a and ORF1ab, four 80 structural genes (spike S, envelope E, membrane M, nucleocapsid N) and accessory proteins are 81 82 all found in the SARS-CoV-2 genome, which has a total length of 30,000 nucleotides [2]. It is through the angiotensin converting enzyme-2 (ACE-2) receptor that the S gene encodes the well-83 known homotrimeric, type I fusion and transmembrane glycoprotein that virus entrance into the 84 host target cell is enabled [3,4]. The virus penetrates the host cell only when two membranes are 85 fused together [4,5]. The cellular type II transmembrane serine proteases (TMPRSS2) are 86 87 activated by SARS-CoV-2, which uses ACE-2 as an entrance receptor (TMPRSS2) [8–10]. The host cell's priming of spike protein is crucial for viral entrance. The effectiveness of SARS-CoV-88 89 2 transmission is determined by this interaction with the ACE-2 [2,6]. Infection and transmission of ACE2 cells in the upper respiratory tract can be increased by exploiting a cellular attachment 90 enhancing factor identified and anticipated in novel mutations [7]. 91

In the ever-growing list of dangerous new agents, SARS-CoV-2 is the most recent. It is difficult to determine the number of asymptomatic COVID-19 infected persons [4,5]. The incubation period for COVID-19 infection is estimated at 2–24 days [6,12,14], and symptoms such as fever, cough, headache, muscle aches, and dyspnoea are usually observed in infected individuals.

Patients with unusual signs and symptoms, such as vomiting and diarrhoea, have been observed
on rare occasions. Global mortality from COVID-19 was reported by WHO as 3.4 % [3]. Over
3.54 billion people have received at least one dose of the SARSCoV-2 vaccines regardless of
brand name as of July 20, 2021. However, this pandemic has become a race between vaccine
efficacy and new variants.

101 Many countries' healthcare system has been strained, and with job losses across industries as a 102 result of this pandemic, which have had unquantifiable economic repercussions [6,7]. Different vaccines have been developed, but the number of confirmed cases and deaths are still rising 103 104 despite these efforts to stop the spread of the disease. The focus has been placed on the necessity to have people vaccinated with WHO-approved COVID-19 vaccines. Previous studies have 105 106 shown that vaccination is an effective means of preventing infectious diseases [8]. However, 107 acceptance of vaccines by people does not always translate into vaccine efficacy and availability. 108 Vaccine hesitancy has been attributed to increasing vaccine misinformation which has markedly contributed to the continuous decrease in vaccine uptake globally, leading to the third and fourth 109 110 waves of the COVID-19 pandemic [9–11].

111 Some of the COVID-19 vaccines developed were made utilising four unique methodologies 112 which incorporates viral vector, whole virus, ribonucleic acid (RNA) and protein subunits [5]. Despite the fact that the COVID-19 jabs were developed more rapidly than previous vaccines, 113 they have been meticulously tried and tested [12]. Vaccine acceptance amongst the overall 114 population and medical workers have a crucial role in the control of the pandemic. The COVID-115 116 19 vaccines are efficacious in preventing COVID-19; however, their effectiveness and viability is dependent upon dosage, seriousness of disease, and COVID-19 variation. For instance, the 117 Pfizer-BioNTech vaccine is estimated at 95 %, Moderna 94.1% and Janssen 66.3 % efficacies 118 119 [4,13,14].

Alpha variant infections are effectively treated with the mRNA COVID-19 vaccines from Pfizer-120 121 BioNTech and Moderna. Sera from a Pfizer-vaccinated health care worker was found to be 122 effective in neutralising B.1.1.7 [6,24]. The Johnson and Johnson single shot is reported to be quite effective in producing protective neutralising antibodies. Moderna and Novavax vaccines 123 124 were found to be less effective at neutralising antibodies. Vaccines from Pfizer-BioNTech and Moderna showed no change in neutralisation of S447N, but lowered neutralisation of E484K. 125 126 Vaccines designed to protect against Beta strains are less effective than those designed to protect 127 against other strains. There was only 75% efficacy for Pfizer's vaccine in clinical trials [18,25], 128 whereas in South African trials, the AstraZeneca AZD1222 vaccine failed to prevent even mild or moderate COVID-19 infection [26]. Good neutralisation was seen with the Covaxin and 129 NVX-CoV2373 (Covavax) vaccines. The vaccines from Pfizer-BioNTech and Moderna have a 130 lower level of neutralising antibodies. 131

In a pre-clinical vivo research, the monoclonal antibody regdanvimab (CT-P59) displayed significant neutralising activity against the Delta variant, B.1.617.2, as well as against the Lambda variant in a cell-based pseudovirus assay. Among antivirals, the most widely used drug is remdesivir which inhibits the viral RNA dependent RNA polymerase and has since been approved by US-FDA for adults and paediatric patients with severe symptoms. China treated 85% of the COVID-19 patients using traditional medicines such as root extract of *Isatis indigotica* and extract of *Houttuynia cordata* [6,7,11].

Roughly, 80-89 % of vaccinated individuals show low rate of local symptoms and 55 – 83 % shows as a minimum of one systemic symptom following immunisation [15]. However, evaluation of attitudes and acceptance rates towards COVID-19 vaccines can shape communication campaigns that are much needed to reinforce trust in vaccination programmes [10]. Vaccination is perhaps the most sustainable intervention to forestall COVID-19 infections

144 [3]. The quickest a vaccine had at any point been created before this pandemic was four years 145 [3,13,16], but COVID-19 vaccines were developed under one year. Vaccine hesitancy mirrors 146 public health hazard [8,17]. The Strategic Advisory Group of Experts on Immunisation (SAGE), 147 defines vaccine hesitancy as the "delay in acceptance or refusal of immunisation regardless of 148 accessibility of immunisation service" [8]. Vaccine hesitancy originates from perceived risks 149 versus benefits, certain strict religious convictions and absence of credible information and 150 mindfulness [12,18–20], and negative perceptions towards COVID-19 vaccines [17,21].

151 In Africa, vaccine hesitancy is premised on perceived danger of the vaccines, safety and 152 effectiveness of vaccines, general immunisation approach, previous immunisation experiences, 153 religious beliefs, immunisation accessibility and socio-cultural constraints [17,22]. A survey by 154 Lazarus et al. [9] revealed vaccine acceptance rate of 81.6 % in South Africa and 65.2 % in 155 Nigeria. A study on early awareness, perception and practices towards COVID-19 vaccines from North-Central Nigeria showed an acceptance rate of 29.0 % [23]. Public health communication 156 needs to assure people of the COVID-19 vaccines safety and their benefits. Awareness of 157 158 COVID-19 vaccines will play a key role in maintaining the public's confidence in vaccination 159 [22,24]. This will require effective communication through adequate resources and planning. Public announcements, advertisement, jingles, webinar, workshops, and trainings are needed to 160 be in place as early as possible and continue until full vaccination is achieved since COVID-19 161 vaccines are now available. This will provide transparent information against rumours and 162 conspiracy theories. Prior knowledge of vaccination shows that most people on the average could 163 164 be willing to accept the COVID-19 vaccines with less side effects. However, awareness 165 campaigns could increase the readiness for COVID-19 vaccination programmes across Africa 166 [17].

167 A key factor in low vaccine acceptance is exposure to misinformation and conspiracy theories. 168 Hesitancy to the COVID-19 vaccines could impede the success of vaccination programmes [25-169 29]. Also, the speed of COVID-19 vaccine development, registration and deployment in less than 170 a year have contributed to the level of hesitancy in Africa [9].

171

172 Materials and Methods

Design of the Study and Participants

174 Using a random selection process, this online cross-sectional survey was conducted at the 175 continental level with randomly selected participants. The interviews were undertaken between December 2020 and March 2021 with the assistance of collaborators from each of the 176 177 participating countries. A questionnaire with 33 question items, separated into four sections, was created. After answering a few demographic questions (such as where you live and what you do 178 179 for a living), respondents were asked a series of questions about their medical and past immunisation history. Our definition for adult Africans refers to Africans aged from 18 years and 180 181 above. The remaining three sections described COVID-19 vaccine's history and how it's 182 administered. Collaborators and the study team reviewed the survey a number of times. Using a piloted sample of 30 people, we tested the questions' reliability and how long it took to interview 183 184 one person. To ensure proper data collection and storage, members of the research team reviewed the data several times a day. 185

The survey questionnaire was created in Microsoft Forms, and was sent by email, and via social media platforms such as Facebook, LinkedIn, Twitter, Telegram, WhatsApp, WeChat and other social media platforms. In this study, participants volunteered their time and were not compensated in any way for their participation. All responses were treated as entirely confidential and were not shared with anyone. In order to reach literate Africans with online

presence, we employed virtual networks to reach the general public using the snowballing or 191 192 chain-referral approach, which saves us both time and money [17]. Even though the representativeness of our survey is compromised by selection bias, we believe that reaching out 193 to Africa's online population is a worthwhile endeavour because vaccine hesitancy among 194 195 Africa's "literate" population has significant ramifications for the rest of the continent's population [18,22]. Social media such as WhatsApp, Facebook and Twitter are popular social 196 media platforms where misinformation, and fake news are communicated and transmitted. Thus, 197 sampling public opinion through these networks, is critical for public health planning [11,25,26]. 198 199 Those who frequent the internet are more likely than others to be linked to networks outside their 200 immediate locations (particularly abroad) and to be affected by online vaccine conspiracies 201 coming from remote locations. Adults without internet access may be persuaded to get the 202 vaccine by those on social media or by word-of-mouth. Our study reporting was done in 203 accordance with the STROBE guidelines [27].

204 Statistical Analyses

Public health specialists with many years of experience in conducting surveys were consulted in the development of the questionnaire [29]. A test group of 20 people took part in the questionnaire before it was rolled out to the public, but they were not included in the final survey. The conventional Cochran formula [29] was used to determine the starting sample size;

209 no =
$$\frac{Z2pq}{g2}$$

where e = the desired precision level (margin of error), where p is the fraction of population, q is 1-p, and Z is the Z-value found in a Z table. A total of 365 participants completed the closedended questionnaire for our study. At a 95% level of confidence, this corresponds to a 2 % margin of error [29].

Descriptive statistics were employed to summarise the survey data and describe the socio-214 215 demographic characteristics of the study participants. Chi-square tests were then used to estimate the correlations between socio-demographic variables and participants' willingness to receive a 216 COVID-19 vaccine. Variables such as likelihood (very likely or somewhat likely), mix (not 217 218 decided), or negative (somewhat unlikely or very unlikely) responses to the COVID-19 vaccine 219 were trichotomised to compare responses for various socio-demographic characteristics. A 220 statistically significant p-value of 0.05 and an alpha level of 5 percent were used to assess 221 potential vaccine hesitancy.

222 Ethical Considerations

Ethical clearance was granted by the Ethics Review Board (ERC) of School of Postgraduate Studies and Research, Amoud University in Somalia. Prior to the data collection, participants were required to provide written consent at the time of data collection. Each participant was asked to sign the form to attest that they had voluntarily chosen to participate in the study. It was made clear that anyone who did not wish to engage in the study had the option to do so. Throughout the survey process, participants' responses were kept completely confidential. All dataset was de-identified to ensure no participant's identity was revealed.

230

231 **Results**

232 Socio-demographic characteristics of respondents

An overview of the demographic profiles of the 365 survey respondents is presented in Table 1 below. The age distribution of the respondents ranged from 65 and above (n = 9; 2.47 %) to 18-29 (n = 169; 46.30 %); indicating the youthfulness of the respondents (Table 1). In terms of gender, the proportion of male participants in the study was 56.99 % compared to 43.01% of female participants in the survey. Majority of the participants were single (55.07 %; n = 201);

238	while 43.01 % (n = 157) were married. On educational attainment, majority of the participants
239	have a university degree (49.86 %; $n = 182$), while 3.56 % ($n = 13$) had basic or secondary
240	school. We also profiled the occupation of the participants. Majority of the participants were
241	students (n = 95; 25.48 %) while 3.56 % (n = 13) were teachers (Table 1). Majority of the
242	participants were Nigerians while the country with the least participation were Malawi, Morocco,
243	Botswana, Cameroon, Democratic Republic of the Congo and Eswatini (Table 1).

244	Table 1.	Demographie	c information	of responde	ents $(n = 365)$	
		(/ I			· · · · · · · · · · · · · · · · · · ·	

Variable	Frequency (n)	Percent (%)
Age		i
18-29	169	46.30
30-49	158	43.29
50-64	29	7.95
65 & Above	9	2.47
Sex		
Male	208	56.99
Female	157	43.01
Marital Status		
Single	201	55.07
Married	157	43.01
Widow(er)	6	1.64
Divorced	1	0.27
Highest Educational Level attended		
Basic/Primary school	1	0.27
Secondary/High school	12	3.29
Diploma	14	3.84
Bachelor's Degree	182	49.86
Master's and Above	156	42.74
Occupation		
Student	93	25.48
Health care worker	69	18.90
University lecturer/researcher	64	17.53
Civil servant	38	10.41
Business man/woman	28	7.67
Professional (Engineer, Accountant, consultant)	21	5.75
Administrator	19	5.21
Teacher	13	3.56
Others	33	29.37
Country of Origin		
Nigeria	174	47.67
Somalia	111	30.41
Ghana	38	10.41
Mozambique	15	4.11
Kenya	5	1.37
Ethiopia	4	1.10
Rwanda	4	1.10

Tanzania	3	0.82
Zambia	3	0.82
Uganda	2	0.55
Malawi	1	0.27
Morocco	1	0.27
Botswana	1	0.27
Congo, Republic of the	1	0.27
Djibouti	1	0.27
Eswatini (formerly Swaziland)	1	0.27
Country of Residence (n = 352)		
Nigeria	169	48.01
Somalia	104	29.55
Ghana	37	10.51
Mozambique	15	4.26
Kenya	4	1.14
Rwanda	4	1.14
Tanzania	3	0.85
Uganda	3	0.85
Zambia	3	0.85
Ethiopia	2	0.57
South Africa	2	0.57
Malawi	3	0.85
Morocco	3	0.85
Botswana	3	0.85
Cameroon	2	0.57
Democratic Republic of the Congo	2	0.57
Eswatini (formerly Swaziland)	2	0.57

245

The socio-demographic characteristics of respondents revealed that social media campaigns yielded the highest awareness (90.4 %), local TV/radio (86.9 %), newspaper (60 %), community mobilisation (4.1 %), religious gatherings (3 %) and courses/flyers (0.6 %) (Figure 1A). However, the respondents considered social media as a more accessible platform to disseminate information for all groups of people.

The result also indicated that one third of the respondents (73 %) do not show interest in taking the COVID-19 test and about one third of the respondents (27 %) have taken COVID-19 test before (Figure 1B). The result of the COVID-19 vaccine acceptability showed variability in the opinions of Africans. The result indicated that about 59 % are willing to receive the COVID-19 vaccine, about 22% respondents were outrightly not in support of the COVID-19 vaccine no matter the directive given by their governments while about 19 % were indifferent about the

vaccine, although this group of people might later change their perspective to receive the vaccine 257 258 or never (Figure 1C).

259 The participants showed low awareness (65 %) of the COVID-19 pandemic while only about one

third (35 %) of the respondents demonstrated some level of awareness (Table 2). Respondents 260

- 261 were asked to give their opinion on whose responsibility it should be in creating the awareness
- 262 with multiple choices provided ranging from the government, media outlets, organisations, and
- 263 individuals. From the survey, 83 % of the respondents believed that the onus for awareness
- 264 campaign is on the government, followed by the media (78 %), health workers (~76 %), WHO
- 265 (~75 %) and about 1% for individuals and community/traditional leaders.

Variable	Frequency (n)	Percent (%)
Do you think enough awareness has been created		
about the COVID-19 Γ		
Yes	126	34.52
No	239	65.48
In your opinion who should be involved in the		
awareness campaign ^Г		
Government ^Γ	303	83.01
Media ^Г	285	78.02
Health Workers Γ	277	75.89
World Health Organisation	272	74.52
Religious leaders	253	69.32
Educational/Research Institution	252	69.04
Centers for Disease Control (CDC)	237	64.93
Civil Society Organisations (CSO)	222	60.82
Industry	151	41.37
Individuals	4	1.10
Community/Traditional leaders	3	0.82
Γ = Multiple response applies		

266 **Table 2.** Awareness among the general public on COVID-19 pandemic (n = 365)

267

268

In measuring public knowledge of the COVID-19 vaccines, we asked questions to assess 269 participants' knowledge on the COVID-19 vaccines. About 26.58 % (n = 97) of the participants 270 271 indicated to have been previously diagnosed with COVID-19; while 73.42 % (n = 268) of the participants indicated they have not been diagnosed with COVID-19 before. Participants were 272

273	also asked what action they will likely take when diagnosed with COVID-19; majority ($n = 144$;
274	39.45 %) revealed they will resort to medications (drugs), 31.23 % ($n = 114$) indicated they will
275	resort to herbal remedies, 21.64% (n = 79) will opt for COVID-19 vaccination (vaccines); while
276	the rest indicated isolation/quarantine, resorting to immune boosting diets, seeking medical
277	attention and prayer as first line of actions (Table 3). Majority of the participants ($n = 197$; 53.97
278	%) indicated they will still accept COVID-19 vaccines even after recovery from an earlier
279	COVID-19 treatment (Table 3). Majority of the participants ($n = 308$; 84.38 %) wrongly ranked
280	the order in which the COVID-19 vaccination should be rolled out at country levels with only
281	15.62 % (n = 57) ranking the vaccine roll out order accurately. Participants disagree/strongly
282	disagree that all COVID-19 prevention protocols such as handwashing, wearing of facemask/face
283	shield, social distancing and use of hand sanitisers should continue even after vaccination (Table
284	3).

Variable	Frequency	Percen
	(n)	(%)
Have you been diagnosed with COVID-19 before		
Yes	97	26.58
No	268	73.42
If you were diagnosed with COVID-19 what will be your first option		
Drugs	144	39.45
Herbal remedies	114	31.23
Vaccine	79	21.64
Isolation/Quarantine	10	2.74
Immune boosting diet	6	1.64
Prayer	5	1.37
Seek medical attention	2	0.55
I don't know	5	1.37
Should I still get the COVID-19 vaccine if I recovered from COVID		
Yes	197	53.97
No	72	19.73
I don't know	96	26.30
In what order should the COVID-19 vaccination be rolled out		
Correct order presented ^µ	57	15.62
Wrong order presented	308	84.38
Hand washing as a COVID-19 Prevention behaviour		
Strongly agree/agree	76	20.82
Disagree/strongly disagree	289	79.18
Wearing of nose or face shield as a COVID-19 Prevention behaviour		

Table 3. Public knowledge on COVID-19 vaccinations (n = 365)

Strongly agree/agree	149	40.82
Disagree/ strongly disagree	216	59.18
Social distancing as a COVID-19 Prevention behaviour		
Strongly agree/agree	147	40.27
Disagree/ strongly disagree	218	59.73
If you have not been vaccinated what can you do to stay safe ^{γ}		
Regular hand washing or use of alcohol-based hand sanitiser	316	86.58
Wearing of nose mask or face shield	297	81.37
Maintaining social distancing	275	75.34
Use of local herbal mixtures	84	23.01
Praying	2	0.55
Maintaining healthy diet and lifestyle	2	0.55
Socially observant for people with symptoms of COVID	1	0.27

286 γ = Multiple response applies; μ = Front-line health workers>Individuals age 50 & above > Individuals age 18 to 49 287 with relevant medical conditions>Government officials & strategic leaders>Individuals age 18 to 49 without 288 relevant medical conditions

289

290 Public perception on the COVID-19 vaccines

291 The perceptions of the participants across diverse countries in Africa was assessed. Among the 292 365 participants, 96.44 % mentioned that COVID-19 vaccines had arrived in their respective 293 countries as at the time of the study. On the contrary, 3.57 % indicated they had no or are not aware of the arrival of the vaccines. Among those who indicated to have knowledge on the 294 295 arrival of vaccines in their countries (n = 352), 76.14 % of them mentioned AstraZeneca vaccine; 296 while 0.28-1.99 % stated either Pfizer-BioNTech, Sinopharm, Johnson and Johnson, Sputnik V 297 or Moderna vaccines. The remaining 19.03 % participants strikingly indicated not to have idea on the brand of vaccine in their countries (Table 4). This trend suggests that AstraZeneca vaccine 298 is the well-known vaccine in the participating countries in this study. 299

Interestingly, 44.89 % of the 352 participants were of the opinion that vaccine brands purchased/arrived in their respective countries are effective against the deadly virus, 42.05 % had no idea on the effectiveness of the vaccines in their countries and the remaining 13.07 % stated emphatically that vaccines in their countries are not effective against the virus (Table 4). Among the reasons ascribed to no effectiveness of vaccines in their countries include not certain on its effectiveness (39.13 %), the associated side effects (28.26 %), and doubts (15.22 %). Prior to

COVID-19 vaccination, 87.95 % of the 365 participants willingly and usually accepted vaccination, but the 12.05 % participants would not willingly accept the COVID-19 vaccination due to some personal reasons. Among the reasons for objection to vaccination include doubts (47.73 %), side effects (34.09 %), healthy condition (2.27 %) and do not want to be used as experimental animals (guinea pigs, 2.27 %) and remaining 13.64 % had no reason for objecting to the vaccination.

Majority of the participants (48.22 %, n = 365) were of the opinion that COVID-19 vaccines are 312 313 safe, while 17.81 % participants believed that the vaccines are not safe and 33.97 % participants 314 had no knowledge on the safety of the vaccines. With regards to the effectiveness of the vaccines, 44.38, 14.52 and 41.10 % indicated that vaccines are effective, ineffective and no 315 knowledge, respectively (Table 4). In addition, 33.97 % participants (n = 365) mentioned that 316 317 COVID-19 vaccines have serious side effects, 32.88 % participants opined that the vaccines have 318 no serious side effects and 33.15 % participants did not know if the vaccines have any serious side effects. Empirically, 41.37 % of the participants (n = 365) had positive perception on the 319 COVID-19 vaccines, while 58.63 % participants had negative perception on the vaccines (Table 320 321 4) probably due to inadequate public education and several conspiracy theories on the vaccines. These results warrant for intensification of public education to counter the numerous conspiracy 322 theories in the public domain. 323

324

325

Table 4. Public perception on the COVID-19 vaccines (n = 365)

Variable	Frequency (n)	Percent (%)
Has COVID-19 arrived in your country		
Yes	352	96.44
No	4	1.10
I don't know	9	2.47
What type of COVID-19 vaccine is available in your country (n =		
352)		
AstraZeneca	268	76.14
Pfizer BioNTech	7	1.99
Sinopharm	4	1.14
Johnson & Johnson	3	0.85
Sputnik V	2	0.57
Moderna	-	0.28
I don't know	67	19.03
Do you think the brand acquired by your country is affective (n -	07	17.05
252)		
JJZ) Vos	158	44.80
les No	130	44.09
NO I don't la out	40	15.07
	148	42.05
Reasons you think the brand is not effective $(n = 46)$	10	20.12
Not certain on its effectiveness	18	39.13
The side effects associated with it	13	28.26
A lot of doubts	7	15.22
Because there is no cure for the COVID-19	2	4.35
Still an experimental drug	2	4.35
Vaccine was developed so quickly	2	4.35
Don't know which variant of virus it is for	1	2.17
Some countries rejected it	1	2.17
Do you normally accept vaccination before		
Yes	321	87.95
No	44	12.05
Reasons for not accepting vaccination (n = 44)		
I have doubts	21	47.73
Side effects	15	34.09
No reason	6	13.64
I am fine and healthy	1	2.27
We are guinea pigs	1	2.27
Do you think the COVID-19 vaccine is safe		
Yes	176	48.22
No	65	17.81
I don't know	124	33.97
Do you think the COVID-19 vaccine is efficacious (effective)		
Yes	162	44.38
No	53	14.52
I don't know	150	41.10
Do you think the COVID-19 vaccine have serious side effects		
Yes	124	33 97
No	120	32.88
I don't know	120	33.15
Averall nublic perception of the COVID 10 vaccines	141	55.15
Positive perception (5-9)	151	<i>A</i> 1 37
Nagative Perception $(5-2)$	214	58.62
	214	30.03

329 Public readiness and willingness to accept COVID-19 vaccines

330 In measuring overall public readiness for the COVID-19 vaccines, 9 questions were used to 331 assess their willingness and readiness. This section was scored 1 for each positive response by 332 the participant, and 0 for each negative response. All answers were summed (as shown in Table 333 5). Participants with an overall willingness to accept the COVID-19 vaccine were scored 5-9, while those not willing to accept the vaccines were scored ≤ 4 . Participants (58.63%; n = 214) not 334 willing to accept the vaccines were proportionally higher, compared to those willing and ready 335 336 (41.37 %; $n = 151^{\circ}$) to accept the vaccines (Table 5). On the other hands, participants were 337 quizzed about the willingness/readiness to pay for the vaccines when available in their countries. Majority of the participants (50 %; n = 109) indicated their unwillingness to pay for the vaccines 338 citing several reasons for their unwillingness. Only 49.30 % (n = 106) of the participants 339 340 indicated their willingness to pay for the vaccines. Most of the participants indicated that their 341 governments are naturally expected to provide the vaccines for free (58 %; n = 56.31), inability to afford the vaccines (36.89 %; n = 38) and skepticism of the efficacy of the vaccines (6.80 %; n 342 343 = 7) to justify their unwillingness to pay for the COVID vaccines (Table 5).

344	Table 5. Put	olic willingness	and readiness	to accept COVI	D-19 vaccines ((n = 365)
		6				· · · · · · · · · · · · · · · · · · ·

Variable	Frequency	Percent
	(n)	(%)
For what reasons are you accepting the vaccine ^{γ}		
It will help me protect my family, friends and others in the community	138	37.81
It will help stop the pandemic	125	34.25
It will prevent me from contracting COVID	109	29.86
The vaccine is safe and effective	102	27.95
It is a requirement for travelling abroad	64	17.53
Are you willing to pay for the vaccine $(n = 215)$		
Yes	106	49.30
No	109	50.70
What is your reason for not willing to pay $(n = 103)$		
Government is expected to provide the vaccine for free	58	56.31
I cannot afford to pay for it	38	36.89
I doubt its effectiveness	7	6.80
Why are you rejecting the vaccine $(n = 79)^{\gamma}$		

I am not sure the vaccine is clinically safe	55	69.62
I am not sure the vaccine is effective in preventing me from contracting	43	54 43
COVID	Ч.Ј	54.45
I am not fully informed about possible side effects of the COVID-19	36	45 57
vaccine	50	15.57
I feel the vaccine in Africa is not the same as the one in other continents,	31	39.24
so I don't trust it	51	37.21
I think the vaccine would alter my DNA	19	24.05
I feel it can result in death, especially among the elderly	18	22.78
I feel there is a tracking device in the vaccine	10	12.65
The vaccine is still under investigations	2	2.53
If more awareness were created and you are satisfied with the safety		
and efficacy (effectiveness) of the COVID-19 vaccine, would you		
accept it? $(n = 79)$		
Yes	29	36.71
No	23	29.11
Maybe	27	34.18
If taking the vaccine becomes a necessary requirement for travel,		
what will you do?		
Avoid travelling	45	56.96
Take the vaccine	30	37.97
I would protest/sue the imposters of such policies	2	2.53
Undecided	2	1.27
Why are you undecided in accepting the COVID-19 vaccine $(n = 71)^{\gamma}$		
I am not sure the vaccine is clinically safe	43	60.56
I am not fully informed about possible side effects of the COVID-19	28	39 44
vaccine	20	37.11
I am not sure if the vaccine in Africa is the same as that in other continents	18	25.35
I am not sure the vaccine is effective in preventing me from contracting	18	25 35
COVID-19	10	20.00
I am not sure if the vaccine would alter my DNA	13	18.31
I feel it can result in death, especially among the elderly	5	7.04
I am not sure if there is a tracking device in the vaccine	4	5.63
I am free from the infection	1	1.41
γ = Multiple response applies		

345 346

We also profiled common myths and conspiracy theories against the COVID vaccines from the respondents. Interestingly, some of the respondents (41.92 %; n = 153) do not subscribe to a conspiracy theory that says the COVID-19 vaccines alter the DNA of recipients; while majority of the respondents (43.29 %; n = 158) are uncertain of the veracity of this myth. Again, 14.79 % (n = 54) of the respondents however subscribed to this conspiracy theory (Table 6). About 10.96 (n = 10.96) of the respondents think the COVID-19 vaccines contain a tracking device, another weird conspiracy theory making waves on social media. However, majority of the respondents

354	(46.85 %; $n = 171$) disagree with this conspiracy theory; with 42.19 % ($n = 154$) of the
355	respondents uncertain about the validity of this myth. The 'COVID-19 vaccine for Africa is
356	different from that in other continents' is among the several myths being circulated in several
357	media outlets. Majority of the respondents (36.44 %; $n = 133$) identify this as a conspiracy
358	theory; while 32.60 % ($n = 119$) agree to this as a truth. Respondents generally revealed that one
359	can still contract COVID-19 even after vaccination (46.03; $n = 168$); while 14.52 % ($n = 53$)
360	indicates it is impossible for a vaccinated person to contract COVID-19 (Table 6).

Variable	Frequency (n)	Percent (%)
Do you think the COVID-19 vaccine will alter your DNA?		
Yes	54	14.79
No	153	41.92
I don't know	158	43.29
Do you think the COVID-19 vaccine contains a tracking		
device?		
Yes	40	10.96
No	171	46.85
I don't know	154	42.19
Do you think the COVID-19 vaccine for Africa is different		
from that in other continents?		
Yes	119	32.60
No	133	36.44
I don't know	113	30.96
Do you think one can still get COVID-19 after vaccination?		
Yes	168	46.03
No	53	14.52
Maybe	144	39.45

Table 6. Myths and socio-cultural perceptions against the vaccines (n = 365)

362

363 Determinants of willingness to accept COVID-19 vaccines among the respondents

364 Willingness to accept COVID-19 vaccines did not vary across socio-demographic variables,

365 except occupational level that showed a significantly higher willingness to accept COVID-19

366 vaccines among the retired (p = 0.042) (Table 7).

367

Variables	Willingness to ac	cept COVID-19	Total	Chi-square,
	vacc	ines		P-value
	Freq	(%)		
	Yes	No		
	N = 215	N = 79		
Age (years)				$p = 0.614^{\mu}$
18-29	100 (70.92)	41 (29.08)	141 (100.0)	_
30-49	88 (72.73)	33 (27.27)	121 (100.0)	
50-64	19 (82.61)	4 (17.39)	23 (100.0)	
65 & Above	8 (88.89)	1 (11.11)	9 (100.0)	
Gender				$\chi 2 = 0.25, p = 0.615$
Male	119 (71.69)	47 (28.31)	166 (100.0)	
Female	96 (75.0)	32 (25.0)	128 (100.0)	
Marital Status				$\chi 2 = 0.84, p = 0.359$
Single	127 (70.95)	52 (29.05)	179 (100.0)	
Married	88 (76.52)	27 (23.48)	115 (100.0)	
Highest Educational				$P = 0.117^{\mu}$
Level				
Primary/Secondary/Hi	0(000)	1(10.0)	10(100.0)	
gh school	9 (90.0)	1 (10.0)	10 (100.0)	
Diploma	6 (46.15)	7 (53.85)	13 (100.0)	
Bachelor's Degree	110 (72.85)	41 (27.15)	151 (100.0)	
Master's and Above	90 (75.0)	30 (25.0)	120 (100.0)	
Occupation				$P = 0.042^{*^{\mu}}$
Business man/woman	19 (90.48)	2 (9.52)	21 (100.0)	
Civil	36 (80.0)	0(200)	<i>45</i> (100 0)	
servant/Administrator	30 (80.0)	9 (20.0)	43 (100.0)	
Company worker	2 (66.67)	1 (33.33)	3 (100.0)	
Health care worker	46 (79.31)	12 (20.69)	58 (100.0)	
Professional	11 (68.75)	5 (31.25)	16 (100.0)	
Retired	5 (100.0)	0 (0.0)	5 (100.0)	
Student/unemployed	52 (60.47)	34 (39.53)	86 (100.0)	
Teacher/University	11 (72 22)	16 (26 67)	60 (100 0)	
Lecturer/researcher	44 (73.33)	10 (20.07)	00 (100.0)	

Table 7. Determinants of willingness to accept COVID-19 vaccines (n = 365)

370 *Statistically significant (p < 0.05), $\mu = Fishers exact p$

371 General factors associated with the willingness to accept COVID-19 vaccines

Respondents' willingness to accept COVID-19 vaccines varied across selected factors (Table 8). Significantly higher acceptability of COVID-19 vaccine was observed among those that have done COVID-19 test before (p = 0.029), normally would accept vaccine before (p = 0.001), and have a positive perception on the safety and effectiveness of the COVID-19 vaccines (p = 0.001). Significantly lower acceptability was observed among those with a perceived myth on the

- 377 COVID-19 vaccine containing a tracking device, which could alter DNA and not the same
- 378 vaccine as the one imported to Africa (p = 0.001).
- **Table 8.** General factors associated with the willingness to accept COVID-19 vaccines (n = 365)

Variables	Willingness to ac vacci Freq	cept COVID-19 ines (%)	Total	Chi-square, P-value
	Yes	No		
	N = 215	N = 79		
Done COVID-19 test before				$\chi 2 = 4.24,$ p = 0.039 *
Yes	69 (82.14)	15 (17.86)	84 (100.0)	•
No	146 (69.52)	64 (30.48)	210 (100.0)	
Normally will accept vaccination before				$\chi 2 = 23.23,$ p = 0.001 *
Yes	200 (78.13)	56 (21.88)	256 (100.0)	•
No	15 (39.47)	23 (60.53)	38 (100.0)	
Positive perception of the safety and				$\chi 2 = 53.77,$ p = 0.001 *
effectiveness of the COVID-19 vaccines				
Yes	127 (94.07)	8 (5.93)	135 (100.0)	
No	88 (55.35)	71 (44.65)	159 (100.0)	
The perceived myth on COVID-19 vaccine				$\chi 2 = 37.39,$ p = 0.001 *
containing a tracking device				•
Yes	12 (38.71)	19 (61.29)	31 (100.0)	
No	129 (88.97)	16 (11.03)	145 (100.0)	
The perceived myth on COVID-19 vaccine				$\chi 2 = 36.42,$ p = 0.001 *
altering human DNA				-
Yes	17 (40.48)	25 (59.52)	42 (100.0)	
No	114 (87.69)	16 (12.31)	130 (100.0)	
The perceived myth that COVID-19 vaccine				$\chi 2 = 40.67,$ p = 0.001 *
for Africa is different				
Yes	48 (51.06)	46 (48.94)	94 (100.0)	
No	105 (91.30)	10 (8.70)	115 (100.0)	

380 **Significant* (*p* < 0.05)

381 Modelling factors associated with COVID-19 vaccine hesitancy

As shown in Table 9, significant explanatory variables in the Chi-Square test of association (Table 9) were included for logistic regression analysis. Model I: Non-adjusted (crude) odds ratio (ORs) comprising selected explanatory variable associated with acceptability of COVID-19 vaccine. The study shows a higher odds ratio for the willingness to accept COVID-19 vaccines

386	among those that have done COVID-19 test before (cOR = 2.02 , 95% CI; $1.07-3.79$, p = 0.029),
387	normally would accept vaccine before (cOR = 5.48 , 95% CI; $2.68-11.19$, p = 0.001), and have a
388	positive perception on the safety and effectiveness of the COVID-19 vaccines (cOR = 12.81,
389	95% CI; 5.87-27.94, p = 0.001). A significant lower odd ratio for acceptability was observed
390	among those with a perceived myth on COVID-19 vaccine containing a tracking device (cOR =
391	0.078, 95% CI; 0.032-0.19, p = 0.001), could alter DNA (cOR = 0.095, 95% CI; 0.043-0.214, p =
392	0.001) and not the same vaccine as the one brought to Africa (cOR = 0.099 , 95% CI; 0.046-
393	0.213, p = 0.001).

Model II: Adjusted ORs comprised selected explanatory variable associated with acceptability of COVID-19 vaccine while controlling for socio-demographic characteristics. After adjusting for confounding variables, only those that have done the COVID-19 test before showed significant higher odd ratio for the willingness to accept the COVID-19 vaccines (aOR = 17.69, 95% CI; 1.21-256.95, p = 0.035). The other variables showed no significant association (p > 0.05).

Table 9. Factors associated with the willingness to accept COVID-19 vaccines (n = 365)

Variables	Model I		Model 1	Ι
_	cOR [95% CI]	P-value	aOR [95% CI]	P-value
Done COVID-19 test				
before No ^R				
Yes	2.02 [1.07-3.79]	0.029*	17.69 [1.21-256-91]	0.035*
Normally will accept vaccination before No ^R				
Yes	5.48 [2.68-11.19]	0.001*	4.11 [0.39-43.79]	0.242
Positive perception of the safety and effectiveness of the COVID-19 vaccines No ^R Yes	12.81 [5.87-27.94]	0.001*	3.17 [0.33-30.55]	0.318
The perceived myth on COVID-19 vaccine containing a tracking device No ^R	0.078 [0.022.0.10]	0.001*	0 10 10 000 1 071	0.057
Yes	0.078 [0.032-0.19]	0.001*	0.10[0.009-1.07]	0.057

The perceived myth on COVID-19 vaccine				
altering human DNA No ^R				
Yes	0.095 [0.043-0.214]	0.001*	0.29 [0.031-2.82]	0.290
The perceived myth				
that COVID-19 vaccine				
for Africa is different				
No ^R				
Yes	0.099 [0.046-0.213]	0.001*	0.45 [0.051-3.89]	0.466

401 *Controlling for Age, Gender, Marital status, educational level and occupation*

402

403 **Discussion**

Vaccine hesitancy can be a significant contributor to the failure to effectively control a pandemic 404 such as the current COVID-19 outbreak [24,28-30]. Consequently, estimates of vaccine 405 acceptance rates can be useful in planning requisite actions and interventions to raise awareness 406 407 and reassure people about the safety and benefits of vaccines, which in turn will aid in controlling the spread of the virus and alleviate the negative effects of the pandemic [11,30,31-408 37]. The assessment of attitudes and acceptance rates of COVID-19 vaccines can aid in the 409 410 development of communication campaigns that are desperately needed to increase public confidence in vaccination programmes [10,15,30–32]. 411

412 We conducted a survey to assess public awareness, vaccine reluctance, and acceptability of 413 COVID-19 vaccines in Africa, as well as the likelihood of participation or non-participation in national government activities to vaccinate persons in each country. According to our data, 414 almost 6 in 10 (55 percent) of mostly urban and adult Africans over the age of 18 years are likely 415 416 to receive the COVID-19 vaccine if it is made widely available, which is consistent with recent 417 findings by Acheampong et al. [29] in Ghana. As the current study demonstrates, social media is 418 extremely important in promoting public awareness of health-related concerns. We established that it was highly effective using social media to disseminate information about COVID-19 419

vaccines in Africa. Local television, radio stations, and newspapers have proven to have a larger reach in spreading information about immunisation programmes in many countries, proving to be particularly effective. The findings of Smith et al. [33] who found that social media is an essential tool used by health authorities and governments in promoting public awareness are consistent with this finding. The relevance of various media in keeping the society informed and watchful in respect to public awareness, knowledge, and readiness to participate in the COVID-19 immunisation campaign was also demonstrated in a report by Anwar et al. [34].

427 A further finding of the survey was that more than 30 % of the participants were unlikely to 428 obtain the vaccine, with another 15 % remaining undecided. Variations in vaccine hesitancy, as 429 well as disparities in critical socio-demographic characteristics were also observed. Again, we 430 found that vaccination resistance is low among older age groups, while males are more likely than females to be indecisive about receiving the vaccine. There were no significant relationships 431 432 found between willingness to receive the vaccines and either education or geographic location in this study. Thus, key stakeholders in the health sector must intensify their efforts in targeted 433 434 public education and promote knowledge about the individual and societal benefits of 435 vaccinations, particularly among younger populations and with a particular emphasis among men 436 to combat the spread of conspiracies and myths [35-39]. A vaccine information campaign should 437 be aimed at decreasing the dissemination of misleading information about the vaccines.

The general public's attitude toward COVID-19 testing was negative, which could be attributed to the inefficiency of the testing regimes in Africa. Some people believe that the COVID-19 pandemic is not genuine and that it is merely a political propaganda, despite the fact that there have been several awareness campaigns at all levels. Consequently, they believe that taking the COVID-19 test will not benefit them and that receiving the vaccine will result in health consequences for themselves. Various conspiracies, such as the vaccinations being created for

advanced nations, are used to justify their reluctance to receive the vaccines [36]. In many cases, 444 445 these conspiratorial beliefs have inflamed public suspicion and raised questions about the 446 efficacy of the vaccines, hampering large-scale immunisation campaigns across the continent. In a study of populations in north-central Nigeria, Lazarus et al. [9] found that just 29 percent of 447 448 those surveyed expressed interest in the COVID-19 vaccines. In addition, a recent Africa CDC 449 [37] report emphasised the importance of addressing issues of faith in vaccines to increase 450 confidence among the public in the management of the COVID-19 pandemic, which is currently 451 ongoing.

452 Increased public awareness of the COVID-19 pandemic is critical to combating the pandemic and preventing the spread of the deadly viral infection that has claimed millions of lives around 453 454 the world. It is the responsibility of the appropriate authorities (African governments, Africa 455 CDC, WHO) to effectively and efficiently disseminate appropriate information to the general 456 public in a timely and space-efficient manner, as well as with closer collaborations between and among these groups to increase public awareness [43-47]. In this way, the risks of infection, 457 458 health consequences, and identification of the most vulnerable population and/or those suffering 459 from comorbidities might all be communicated in one voice [11,34, 45-47]. This would also help to minimise the spread of disinformation, misinformation, and conspiracies, as well as facilitate 460 early detection and intervention in the fight against the virus (e.g., vaccination). 461

It is possible that several participants were excluded from the study because of the lack of stable internet connection, even though data indicates high internet penetration rates and mobile phone use across Africa. This was a cross-sectional study, and thus no causal links can be established between the independent and dependent variables. Additional time points should be included in future survey to further understand how people's attitudes toward vaccination change over time.

467 Policymakers may assess how vaccination hesitancy might change as a result of the emerging468 mutations of COVID-19.

469 **Conclusion**

COVID-19 vaccination was a 'no-go-area' for less than two-thirds of African adults surveyed, 470 471 with a large proportion of those surveyed expressing doubts on the efficacy of the vaccines. 472 Many of the people who would not get vaccinated could have an impact on the implementation of a COVID-19 immunisation programme intended for everyone. In order to prevent the harmful 473 474 effects of their views on others, health ministries should intensify awareness to counter such 475 extreme views against the vaccines. There is a risk that the results of a survey can be interpreted 476 incorrectly because of the method used to distribute questionnaires. Our social media outreach 477 may have excluded many low-income and elderly persons, as well as those with no or minimal education. Consequently, the results of this survey may not be indicative of the desires and 478 hesitancy of the entire African countries that were surveyed. The vaccines were not available at 479 the time of the survey; therefore, the results may have been different from respondents who 480 received a vaccine. 481

482

- 483 **Supporting information**
- 484 S1. Raw dataset from survey (XLSX)

485 **Declaration of Competing Interest**

The authors declare no conflict of interest. All authors attest they meet the ICMJE criteria forauthorship

488 Acknowledgments

We thank all collaborating institutions and partners who circulated the data collectioninstruments in their networks.

491 Authors' contributions

- 492 Conceptualisation, JKA, FVD, OMA and NTC; methodology, FEA, KOE, and IL; software,
- 493 JKA, FEA, IBG, and CLO; validation, OMA, BK, FVD; formal analysis, NTC, IAA, STF and
- 494 MAN; investigation, JKA, HGD, BK, GPM and SOA; data curation, DUO, STA, IAA, and NTC;
- 495 writing-original draft preparation, KOE, JKA, OMA, BK, IAA, NTC, FEA and HGD;
- 496 writing—review and editing, JKA, FVM, NTC, FEA, IBG; visualisation, FEA, NTC and IAA;
- 497 supervision, FVM; project administration, JKA. All authors have read and agreed to the
- 498 published version of the manuscript.
- 499

500 **References**

Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV
 epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus
 outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020. pp. 264-266.
 https://doi.org/10.1016/j.ijid.2020.01.009

- WHO. Coronavirus disease 2019 (COVID-19) Situation Report-86. 2020. Available:
 https://www.who.int/teams/risk-communication/infodemic-management
- 508

505

3. Zhou P, Yang X lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature 2020 579:7798. 2020;579: 270273. <u>https://doi.org/10.1038/s41586-020-2012-7</u>

512

4. Chan JFW, Kok KH, Zhu Z, Chu H, To KKW, Yuan S, et al. Genomic characterization of the
2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after
visiting Wuhan. Emerging Microbes & Infections. 2020;9: 221-236.
https://doi.org/10.1080/22221751.2020.1719902

- 517
- 5. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Advances in Virus
 Research. 2019;105: 93-116. <u>https://doi.org/10.1016/bs.aivir.2019.08.002</u>
- 520

521 6. Thakur V, Bhola S, Thakur P, Patel SKS, Kulshrestha S, Ratho RK, et al. Waves and variants
522 of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. Infection.
523 2021. https://doi.org/10.1007/s15010-021-01734-2

7. Rishi P, Thakur K, Vij S, Rishi L, Singh A, Kaur IP, et al. Diet, Gut Microbiota and COVID19. Indian Journal of Microbiology. 2020. pp. 420-429. <u>https://doi.org/10.1007/s12088-020-</u>
00908-0

- 528
- 8. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease
- 531 inhibitor. Cell. 2020;181: 271-280.e8. <u>https://doi.org/10.1016/j.cell.2020.02.052</u>
- 532
- 9. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARSCoV-2 by full-length human ACE2. Science. 2020;367: 1444-1448.
 https://doi.org/10.1126/science
- 536

537 10. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. SARS-CoV-2 and 538 bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. 539 Nature Structural & Molecular Biology 2020 27:8. 2020;27: 763-767. https://doi.org/10.1038/s41594-020-0468-7 540

- 541
- 542 11. Patel SKS, Lee JK, Kalia VC. Deploying Biomolecules as Anti-COVID-19 Agents. Indian
 543 Journal of Microbiology. Springer; 2020. pp. 263-268. <u>https://doi.org/10.1007/s12088-020-</u>
 544 <u>00893-4</u>
- 545

12. Park YJ, Walls AC, Wang Z, Sauer MM, Li W, Tortorici MA, et al. Structures of MERSCoV spike glycoprotein in complex with sialoside attachment receptors. Nature Structural &
Molecular Biology 2019 26:12. 2019;26: 1151-1157. <u>https://doi.org/10.1038/s41594-019-0334-7</u>

13. Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. Microneedle array
delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational
development. EBioMedicine. 2020;55: 102743. <u>https://doi.org/10.1016/j.ebiom.2020.102743</u>

14. Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an
emerging coronavirus infection: advances and prospects in designing and developing vaccines,
immunotherapeutic, and therapeutics. Human Vaccines and Immunotherapeutic. 2020. pp. 12321238. <u>https://doi.org/10.1080/21645515.2020.1735227</u>

558

15. Elhadi M, Alsoufi A, Alhadi A, Hmeida A, Alshareea E, Dokali M, et al. Knowledge,
attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine: a
cross-sectional study. BMC Public Health. 2021; 21.

562 <u>https://doi.org/10.1186/s12889-021-10987-3</u>

16. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 Vaccine Acceptance in Saudi 564 565 Arabia: A Web-Based National Survey. Journal of Multidisciplinary Healthcare. 2020;13: 1657-566 1663. https://doi.org/10.2147/JMDH.S276771

567

17. Habersaat KB, Betsch C, Danchin M, Sunstein CR, Böhm R, Falk A, et al. Ten 568 569 considerations for effectively managing the COVID-19 transition. Nature Human Behaviour 2020 4:7. 2020;4: 677-687. https://doi.org/10.1038/s41562-020-0906-x 570

571

572 18. Lazarus J v., Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine 2020 27:2. 2020;27: 225-228. 573 574 https://doi.org/10.1038/s41591-020-1124-9

575

576 19. Lin C, Tu P, Beitsch LM. Confidence and Receptivity for COVID-19 Vaccines: A Rapid 577 Systematic Review. Vaccines 2021, Vol 9. Page 16. 2020;9: 16. 578 https://doi.org/10.3390/vaccines9010016

579

580 20. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet Regional Health-Europe. 581 582 2021;1: 100012. https://doi.org/10.1016/j.lanepe.2020.100012

583

584 21. Sallam M. Covid-19 vaccine hesitancy worldwide: A concise systematic review of vaccine 585 acceptance rates. Vaccines. 2021. pp. 1-15. https://doi.org/10.3390/vaccines9020160

2020:35:

43-49.

586 22. Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: The current 587 state Respiratory Reviews. 588 of play. Paediatric

https://doi.org/10.1016/j.prrv.2020.06.010 589

590

591 23. Shih HI, Wu CJ, Tu YF, Chi CY. Fighting COVID-19: A quick review of diagnoses, 592 vaccines. Biomedical Journal. therapies, and 2020;43: 341-354. 593 https://doi.org/10.1016/j.bj.2020.05.021

594

595 24. Araf Y, Akter F, Tang Y, Fatemi R, Parvez MdSA, Zheng C, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. Journal 596 597 of Medical Virology. 2022. https://doi.org/10.1002/jmv.27588

598

25. Weintraub RL, Subramanian L, Karlage A, Ahmad I, Rosenberg J. COVID-19 Vaccine to 599 600 Vaccination: Why leaders must invest in Delivery Strategies Now. Health Affairs. 2021:40: 33-601 41. https://doi.org/10.1377/hlthaff.2020.01523

26. Adigwe OP. COVID-19 vaccine hesitancy and willingness to pay: Emergent factors from a

Vaccine:

X.

2021;9:

100112.

Nigeria.

603 604

cross-sectional

study

in

605 https://doi.org/10.1016/j.jvacx.2021.100112 606 607 27. Malik AA, McFadden SAM, Elharake J, Omer SB. Determinants of COVID-19 vaccine 608 acceptance in the US. EClinicalMedicine. 2020;26. https://doi.org/10.1016/j.eclinm.2020.100495 609 28. Rebold N, Holger D, Alosaimy S, Morrisette T, Rybak M. COVID-19: Before the Fall, An 610 Evidence-Based Narrative Review of Treatment Options. Infectious Diseases and Therapy. 611 2021;10: 93-113. https://doi.org/10.1007/s40121-021-00399-6 612 613 29. Acheampong T, Akorsikumah EA, Osae-Kwapong J, Khalid M, Appiah A, Amuasi JH. 614 615 Examining vaccine hesitancy in sub-Saharan Africa: A survey of the knowledge and attitudes 616 covid-19 among adults to receive vaccines in ghana. Vaccines. 2021;9. 617 https://doi.org/10.3390/vaccines9080814 618 30. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine 619 hesitancy: the next challenge in the fight against COVID-19. European Journal of Epidemiology. 620 2020;35: 775-779. https://doi.org/10.1007/s10654-020-00671-y 621 622 623 31. Nemat A, Bahez A, Salih M, Raufi N, Noor NAS, Essar MY, et al. Public willingness and hesitancy to take the COVID-19 vaccine in Afghanistan. American Journal of Tropical Medicine 624 and Hygiene. 2021;105: 713-717. https://doi.org/10.4269/ajtmh.21-0231 625 626 627 32. Nemat A, Bahez A, Salih M, Raufi N, Noor NAS, Essar MY, et al. Public Willingness and Hesitancy to Take the COVID-19 Vaccine in Afghanistan. The American Journal of Tropical 628 Medicine and Hygiene. 2021;105: 713-717. https://doi.org/10.4269/ajtmh.21-0231 629 630 33. Shacham M, Greenblatt-Kimron L, Hamama-Raz Y, Martin LR, Peleg O, Ben-Ezra M, et al. 631 632 Increased covid-19 vaccination hesitancy and health awareness amid covid-19 vaccinations 633 programs in Israel. International Journal of Environmental Research and Public Health. 2021;18. https://doi.org/10.3390/ijerph18073804 634 635 34. Reuben RC, Danladi MMA, Saleh DA, Ejembi PE. Knowledge, Attitudes and Practices 636 Towards COVID-19: An Epidemiological Survey in North-Central Nigeria. Journal of 637 Community Health. 2021;46: 1. https://doi.org/10.1007/s10900-020-00881-1 638 639 640 35. Palamenghi L, Barello S, Boccia S, Graffigna G. Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy. European Journal of 641 642 Epidemiology. 123AD;1: 3. https://doi.org/10.1007/s10654-020-00675-8 643 30

36. French J, Deshpande S, Evans W, Obregon R. Key Guidelines in Developing a Pre-Emptive 644 645 COVID-19 Vaccination Uptake Promotion Strategy. International Journal of Environmental 646 Public Health 2020, Vol 17, 5893. 2020;17: 5893. Research and Page 647 https://doi.org/10.3390/ijerph17165893

648

649 37. Cobos Muñoz D, Monzón Llamas L, Bosch-Capblanch X. Exposing concerns about
650 vaccination in low- and middle-income countries: a systematic review. Int J Public Health.
651 2015;60: 767-780. <u>https://doi.org/10.1007/s00038-015-0715-6</u>

652

38. Erick von Elm, Douglas G. Altman, Matthias Egger, Stuart J. Pocock, Peter C. Gotzche, Jan
P. Vandenbroucke. The Strengthening of the Reporting of Observational Studies in
Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS
Medicine. 2007;4: e296. <u>https://doi.org/10.1371/journal.pmed.0040296</u>

657

39. Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based
mitigation measures influence the course of the COVID-19 epidemic? Lancet. 2020;395: 931934. <u>https://doi.org/10.1016/S0140-6736(20)30567-5</u>

661

40. Benecke O, DeYoung SE. Anti-vaccine decision-making and measles resurgence in the
United States. Global Pediatr Health. 2019; 6: 1-5. <u>https://doi.org/10.1177/2333794X19862949</u>

41. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. European Journal of
Epidemiology 2020 35:4. 2020;35: 325-330. <u>https://doi.org/10.1007/s10654-020-00634-3</u>

42. Karlsson LC, Soveri A, Lewandowsky S, Karlsson L, Karlsson H, Nolvi S, et al. Fearing the
disease or the vaccine: The case of COVID-19. Personality and Individual Differences.
2021;172: 110590. <u>https://doi.org/10.1016/j.paid.2020.110590</u>

671

667

43. al Awaidy ST, Khamis F. Preparing the community for a vaccine against COVID-19. Oman
Medical Journal. Oman Medical Specialty Board; 2020. pp. 1-3.
<u>https://doi.org/10.5001/omj.2020.130</u>

675

 676
 44. Smith N, Graham T. Mapping the anti-vaccination movement on Facebook.

 677
 https://doi.org/101080/1369118X20171418406.
 2017;22:
 1310-1327.

 678
 https://doi.org/10.1080/1369118X.2017.1418406
 2017;22:
 1310-1327.

679

45. Anwar A, Malik M, Raees V, Anwar A. Role of Mass Media and Public Health
Communications in the COVID-19 Pandemic. Cureus. 2020.
https://doi.org/10.7759/cureus.10453

- 683 46. Yesse M, Muze M, Kedir S, Argaw B, Dengo M, Nesre T, et al. Assessment of knowledge,
- attitude and practice toward COVID-19 and associated factors among health care workers in Silte
- Zone, Southern Ethiopia. PLoS ONE. 2021;16. <u>https://doi.org/10.1371/journal.pone.0257058</u>
- 686
- 47. Africa CDC. Research and Development Priorities for COVID-19 in Africa. 2021.

